|Heron Therapeutics, Inc.|
123 Saginaw Drive
United States - Map
Heron Therapeutics, Inc., a biotechnology company, develops products to address unmet medical needs using its proprietary Biochronomer polymer-based drug delivery platform. The company's drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by extending the duration of action of known active ingredients. Its lead product candidate, SUSTOL (granisetron injection, extended release), is being developed for the prevention of acute- and delayed-onset chemotherapy-induced nausea and vomiting. The company's product development program also focuses on identifying new delivery methods and formulations utilizing known compounds that may expand or extend the therapeutic effort, or eliminate the drawbacks of current therapies. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Redwood City, California.
|Heron Therapeutics, Inc.’s ISS Governance QuickScore as of Feb 1, 2015 is 7. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 6; Compensation: 9.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Dr. Barry D. Quart Pharm.D.,
Chief Exec. Officer and Director
|Mr. Robert H. Rosen ,
Pres and Director
|Mr. Brian G. Drazba CPA,
Chief Financial Officer and VP of Fin.
|Mr. Paul G. Marshall ,
Sr. VP of Technical Operations
|Ms. EsmÃ© C. Smith J.D.,
VP, Gen. Counsel and Sec.
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|